Vector Purification Research Report 2025-2035: 100+ Products, 1,000+ Clinical Trials And Rising Demand For Adenoviral And Lentiviral Therapies Drive Global Growth

(MENAFN- GlobeNewsWire - Nasdaq) The vector purification market offers significant growth potential due to increasing demand for viral vectors in gene and cell therapies and vaccines. Opportunities lie in developing scalable purification techniques, particularly affinity chromatography. The market is driven by North American companies, with substantial demand in oncology and neurological disorders.

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Vector Purification Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Viral Vector, Type of Purification Technique, Type of Therapy, Therapeutic Area, Scale of Operation, and Key Geographical Regions" report has been added to ResearchAndMarkets's offering.

The global vector purification market valued at USD 155 million in the current year is anticipated to grow at a lucrative CAGR of 21% during 2025-2035

Viral vectors are the biological tools that are used to transport genetic material to the target cell. Despite being a complex and resource-intensive process, development and manufacturing of cell and gene therapies has gained substantial momentum, with an increasing number of clinical programs moving to later-phase clinical trials and towards market approval.

There are currently over 30 commercially available cell and gene therapy products, along with hundreds of ongoing clinical trials for these innovative therapies. Furthermore, the COVID-19 pandemic has led to a notable rise in the number of therapies that are currently under intervention in clinical trials. However, the current purification methods for viral vectors involve a multitude of steps, which are known to be associated with high product losses and lower yields.

Gradually, rising demand for viral vectors coupled with lack of scalability and other concerns related to downstream purification, have led stakeholders in this domain to undertake various initiatives to develop novel and effective solution for virus purification. Recently, stakeholders have begun relying more on affinity chromatography-based virus purification regimens. Further, there are several companies that claim to offer a diverse range of innovative solutions for vector purification, including filter plates, prepacked chromatography columns and resins, and consolidated kits.

Vector Purification Market: Key Insights

• Over 100 viral vector purification products, involving the use of a variety of downstream processing techniques, have been developed to improve virus recovery and facilitate effective removal of contaminants / impurities.
• Most of the available virus purification products have been designed for small / clinical scale use, catering to specific requirements of different types of vectors; North America emerged as the hub of development of such solutions.
• Given the surge in R&D on viral vector-based vaccines in the current crisis, the demand for large scale virus purification solutions is anticipated to be on the rise.
• Adenoviral vectors are widely used in cell and gene therapies; hence, several players offer products, such as kits, resins and columns, for such viruses.
• Majority of developers are based in North America; Bio-Rad Laboratories, Cytiva and Thermo Fisher Scientific are some of the large players based in the region.
• Over the years, more than 1,000 clinical trials, evaluating various viral vector-based therapies and vaccines, across a wide range of diseases, have been registered and are being conducted in different global regions.
• In order to augment and further optimize existing virus purification processes, several viral vector drug developers and manufacturers are likely to forge alliances with purification product developers.
• Over 35 players across the globe are capable of manufacturing different types of viral vectors at commercial scale, either for in-house requirements or as part of contract manufacturing engagements.
• Owing to the rise in R&D initiatives focused on viral cell and gene therapies, the clinical and commercial demand for various types of viral vectors is expected to increase, across a variety of therapeutic indications.
• Since only a few genetically modified therapies have been approved, the current demand is being driven by the patients enrolled in various clinical trials for viral vector-based therapies.
• Currently, over 40% of commercial demand is attributed to adenoviruses due to their wide use in marketed therapies; further, lentiviruses contribute to about 35% of the clinical demand.
• Majority of viral vectors are being developed for patients suffering from oncological disorders; in the coming years, neurological disorders and muscular disorders, are likely to generate a significant demand.
• The market is anticipated to grow at a CAGR of over 21% during the forecast period, and the opportunity is likely to be distributed across different types of purification techniques, viral vectors and key geographical regions.

Vector Purification Market: Research Coverage

• Strategic Partner Analysis: A detailed analysis of the potential strategic partners for viral vector purification product developers, based on various parameters, such as type of viral vector, developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.
• Clinical Trial Analysis: An in-depth analysis of clinical studies of different viral-vector based therapies, examining factors, such as registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, geographical location, number of patients enrolled and key players.
• Demand Analysis: A detailed analysis of the current and future demand for viral vectors, based on various parameters, such as target patient population, dosing frequency, dose strength, type of viral vector, type of therapy, therapeutic are and geographical location.
• Case Study 1: A detailed discussion on tangential flow filtration (TFF), representing the role, advantages and disadvantages of the various techniques used for purification of viral vectors; featuring the details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.
• Case Study 2: Elaborate assessment of viral vector manufacturers providing commercial scale production, focusing on details, such as year of establishment, company size, type of viral vector, purpose of production, location of headquarters and manufacturing facilities.

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Players in the Vector Purification Market Profiled in the Report

• Agilent Technologies
• BIA Separations
• Bio-Rad Laboratories
• BioVision
• Cytiva (formerly GE Lifesciences)
• Merck
• Sartorius
• Takara Bio
• Thermo Fisher Scientific

Report Scope:

Type of Viral Vector

• AAV
• Adenovirus
• Lentivirus
• Retrovirus
• Others

Type of Purification Technique

• Chromatography
• Centrifugation
• Filtration

Type of Therapy

• Gene Therapy
• Cell Therapy
• Viral Vaccines

Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Ophthalmic Disorders
• Metabolic Disorders
• Inflammation & Immunological Diseases
• Others

Scale of Operation

• Preclinical / Clinical
• Commercial

Key Geographical Regions

• North America
• Europe
• Asia- Pacific
• Rest of the World

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachments

• Viral Vector Purification Products
• Clinical Trial Analysis

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01102025004107003653ID1110134566